Prostate Cancer Clinical Trials

Trials for someone you care about with prostate cancer.

Cancer

RecruitingDrugDeviceBehavioralOlder adultsHealthy volunteers

83 trials · showing 30

Comparing 3 approaches for metastatic castration-resistant prostate cancer (mcrpc)

Explore this study →

There are 3 groups in this study. Group A receives INR731, together with one or more of: Androgen deprivation therapy (ADT). Group B receives INR731 and Enzalutamide, together with one or more of: Androgen deprivation therapy (ADT). Group C receives INR731 and Abiraterone, together with one or more of: Androgen deprivation therapy (ADT).

Sites in Montreal and Toronto

  • Phase 1
  • 3 groups
  • Sites in Toronto and Montreal
  • Recruiting

Official title: A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Novartis Pharmaceuticals

Comparing Bone Scan with External Beam Radiation Therapy for prostate adenocarcinoma

Explore this study →

There are 2 groups in this study. Group A receives one or more of: Biospecimen Collection, Bone Scan, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration and Stereotactic Body Radiation Therapy. Group B, the comparison group, receives one or more of: Biospecimen Collection, Computed Tomography, External Beam Radiation Therapy, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment and Questionnaire Administration.

Sites in Montreal, Toronto and 4 more cities

  • Phase 3
  • 2 groups
  • Sites in Saint John, Ottawa and 4 more cities
  • Recruiting

Official title: Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer

Prostate Adenocarcinoma · NRG Oncology

Comparing Opevesostat with Abiraterone acetate for metastatic castration-resistant prostate cancer (mcrpc)

Explore this study →

There are 2 groups in this study. Group A receives Opevesostat, together with one or more of: Dexamethasone, Fludrocortisone acetate and Hydrocortisone. Group B, the comparison group, receives one or more of: Abiraterone acetate, Prednisone acetate and Enzalutamide.

Sites in Abbotsford British Columbia, Edmonton and 5 more cities

  • Phase 3
  • 2 groups
  • Sites in Edmonton, Abbotsford British Columbia and 5 more cities
  • Recruiting

Official title: A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

Metastatic Castration-resistant Prostate Cancer (mCRPC) · Merck Sharp & Dohme LLC

Testing Saruparib against a placebo for prostate cancer

Explore this study →

There are 4 groups in this study. Group A receives Saruparib, together with one or more of: Androgen Deprivation Therapy (ADT). Group B, the placebo group, receives Placebo, together with one or more of: Androgen Deprivation Therapy (ADT). Group C receives Saruparib, together with one or more of: Abiraterone + Prednisolone/Prednisone and Androgen Deprivation Therapy (ADT). …and 1 more groups.

Sites in Toronto, Abbotsford British Columbia and 8 more cities

  • Phase 3
  • 4 groups
  • Sites in Calgary, Abbotsford British Columbia and 8 more cities
  • Recruiting

Official title: A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

Prostate Cancer · AstraZeneca

Comparing 10 approaches for progressive metastatic castrate resistant prostate cancer

Explore this study →

There are 10 groups in this study. Group A receives one or more of: Tulmimetostat DL1 QD and JSB462 Dose 1 QD. Group B receives one or more of: Tulmimetostat DL1 QD and JSB462 Dose 2 QD. Group C receives one or more of: Tulmimetostat DL2 QD and JSB462 Dose 1 QD. …and 6 more groups.

One site, in Halifax

  • Phase 1
  • 10 groups
  • One site, in Halifax
  • Recruiting

Official title: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)

Progressive Metastatic Castrate Resistant Prostate Cancer · Novartis Pharmaceuticals

Comparing 5 approaches for metastatic hormone-sensitive prostate cancer (mhspc)

Explore this study →

There are 5 groups in this study. Groups A, C and D receive one or more of: Tulmimetostat, Darolutamide and Androgen Deprivation Therapy (ADT). Group B receives one or more of: Tulmimetostat, Abiraterone, Prednisone/Prednisolone and Androgen Deprivation Therapy (ADT). Group E, the comparison group, receives one or more of: Darolutamide and Androgen Deprivation Therapy (ADT).

One site, in Montreal

  • Phase 1
  • 5 groups
  • One site, in Montreal
  • Recruiting

Official title: TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) · Novartis Pharmaceuticals

Looking for the closest fit?

Get matched →

Ask someone to look with you

Whether or not the results above are what you were looking for, someone at Concord can search with you.

Get notified when a matching trial opens

We'll watch for Prostate Cancer trials near you.

Prostate Cancer
Want matched now instead? →
← Back to all conditions

Concord provides information support only. Trial listings come from public registries; eligibility is always determined by the trial site and your care team.